New hope for rare stomach cancer: drug cocktail shows promise in early trial

This study tests a combination of chemotherapy drugs and an immunotherapy drug for a rare and aggressive type of stomach cancer called hepatoid adenocarcinoma. About 30 people with locally advanced, HER2-negative cancer will receive the treatment before and after surgery. The goal is to see if this approach can shrink tumors and improve outcomes, while also checking for side effects.